Products listed on this website are the main products that Astellas provides globally. These products may not be available in all countries or regions and may be available under different brand names and trademarks, for different indications and patient populations, in different dosages, and in different strengths. These products generally are available only by prescription through local healthcare professionals.
Please visit our local country or region websites for local product information.

XTANDI® (enzalutamide)

XTANDI is a treatment for prostate cancer.

XOSPATA® (gilteritinib)

XOSPATA is a treatment for patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation.

PADCEV® (enfortumab vedotin)

PADCEV is a treatment for patients with locally advanced or metastatic urothelial cancer who have previously received other treatments.

Evrenzo® (roxadustat)

Evrenzo is a treatment for anemia associated with chronic kidney disease (CKD). 

Betanis®/Myrabetriq™/BETMIGA™ (mirabegron)

Betanis/Myrabetriq/BETMIGA is a treatment for overactive bladder (OAB).

Prograf® and Advagraf™/Graceptor®/ASTAGRAF XL™ (tacrolimus)

Prograf and Advagraf/Graceptor/ASTAGRAF XL are immunosuppressants.

 

 

Please refer to the Supplementary Documents (pdf) of the Business Results in regard to the sales of major products in each region, including the products above.